The molecular aspects in prostatic cancer, unraveling the role of CDKs in prostate cancer progression.

IF 2.9 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Discover. Oncology Pub Date : 2025-10-15 DOI:10.1007/s12672-025-03605-w

Zahra Farjami, Zahra Mohammadzadeh, Bita Saifi, Mahasti Tavakoli Nezhad, Mohammad Mehdi Akbarin

{"title":"The molecular aspects in prostatic cancer, unraveling the role of CDKs in prostate cancer progression.","authors":"Zahra Farjami, Zahra Mohammadzadeh, Bita Saifi, Mahasti Tavakoli Nezhad, Mohammad Mehdi Akbarin","doi":"10.1007/s12672-025-03605-w","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer (PCa) is one of the leading causes of morbidity and mortality in the world, it becomes imperative to investigate the molecular mechanisms underlying practical therapeutic approaches. Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression, and their dysregulation has been implicated in PCa.Methods: This review synthesizes recent findings on CDK-mediated signaling pathways and their role in PCa progression. The overall goal of this review article is to elucidate the molecular mechanisms by which CDK molecules contribute to the development, progression, and metastasis of PCa.Results: Elevated expression of CDK1, CDK3, CDK5, and CDK16 is associated with poorer outcomes, and specifically, high CDK3 expression correlates with shorter progression-free survival.Conclusions: Targeting CDKs, particularly CDK3 and CDK4/6, may represent a promising therapeutic strategy for PCa.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1900"},"PeriodicalIF":2.9000,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12528570/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03605-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate cancer (PCa) is one of the leading causes of morbidity and mortality in the world, it becomes imperative to investigate the molecular mechanisms underlying practical therapeutic approaches. Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression, and their dysregulation has been implicated in PCa.

Methods: This review synthesizes recent findings on CDK-mediated signaling pathways and their role in PCa progression. The overall goal of this review article is to elucidate the molecular mechanisms by which CDK molecules contribute to the development, progression, and metastasis of PCa.

Results: Elevated expression of CDK1, CDK3, CDK5, and CDK16 is associated with poorer outcomes, and specifically, high CDK3 expression correlates with shorter progression-free survival.

Conclusions: Targeting CDKs, particularly CDK3 and CDK4/6, may represent a promising therapeutic strategy for PCa.

Abstract Image

查看原文本刊更多论文

前列腺癌的分子方面，揭示CDKs在前列腺癌进展中的作用。

背景：前列腺癌（PCa）是世界上发病率和死亡率最高的疾病之一，研究其分子机制和治疗方法势在必行。细胞周期蛋白依赖性激酶（CDKs）是细胞周期进程的关键调节因子，其失调与PCa有关。方法：本文综述了cdk介导的信号通路及其在前列腺癌进展中的作用的最新发现。这篇综述文章的总体目标是阐明CDK分子参与PCa发生、进展和转移的分子机制。结果：CDK1、CDK3、CDK5和CDK16的表达升高与较差的预后相关，特别是CDK3的高表达与较短的无进展生存期相关。结论：靶向CDKs，特别是CDK3和CDK4/6，可能是一种有希望的PCa治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊